1. Dorey, E. Nat. Biotechnol. 31, 774 (2013).
2. European Medicines Agency. CHMP Assessment Report for Filgrastim Hexal. (no. EMEA/CHMP/651324/2008)
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000918/WC500022471.pdf
(2008).
3. European Medicines Agency. European Public Assessment Report for Binocrit.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf
(2007).
4. European Medicines Agency. CHMP Assessment Report for Remsima. (no. EMA/CHMP/589317/2013)
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf
(2013).
5. European Medicines Agency. CHMP Draft Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. (no. CHMP EMEA/CHMP/BMWP/42832/2005, rev. 1)
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf
(2006).